Currently, there are 120.41M common shares owned by the public and among those 120.14M shares have been available to trade.
The company’s stock has a 5-day price change of 9.27% and -18.07% over the past three months. HUM shares are trading -44.17% year to date (YTD), with the 12-month market performance down to -43.61% lower. It has a 12-month low price of $213.31 and touched a high of $475.00 over the same period. HUM has an average intraday trading volume of 2.56 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.25%, -6.30%, and -21.04% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Humana Inc (NYSE: HUM) shares accounts for 94.78% of the company’s 120.41M shares outstanding.
It has a market capitalization of $30.77B and a beta (3y monthly) value of 0.55. The stock’s trailing 12-month PE ratio is 22.63, while the earnings-per-share (ttm) stands at $11.29. The company has a PEG of 9.02 and the debt-to-equity ratio at 0.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.14% over the week and 3.61% over the month.
Earnings per share for the fiscal year are expected to decrease by -38.11%, and 5.37% over the next financial year. EPS should shrink at an annualized rate of 2.51% over the next five years, compared to 10.46% over the past 5-year period.
Looking at the support for the HUM, a number of firms have released research notes about the stock. BofA Securities stated their Neutral rating for the stock in a research note on November 06, 2024, with the firm’s price target at $247-$308. Bernstein was of a view on October 08, 2024 that the stock is Outperform, while TD Cowen gave the stock Hold rating on October 07, 2024, issuing a price target of $402- $261. Jefferies on their part issued Hold rating on October 07, 2024.
